Sodium adenosine triphosphate (ATP),10 mg/ml 1 ml 10 pcs

Sodium adenosine triphosphate (ATP) is a metabolic agent, has an antiarrhythmic effect, also has a hypotensive effect, dilates coronary and cerebral arteries. It is a natural macroergic compound. It is formed in the body as a result of oxidative reactions and in the process of glycolytic breakdown of carbohydrates. It is found in many organs and tissues, but most of all in the skeletal muscles. It improves metabolism and energy supply of tissues.

Afterwards the products of cleavage are included in ATP resynthesis. The antiarrhythmic action is caused by adenosine formed during ATP decomposition, which inhibits automatism of sinus-atrial node and Purkinje fibers (blockade of calcium channels and increase of permeability for potassium ions).

Indications

In the complex therapy of muscular dystrophy and atrophy; for relief of paroxysms of supraventricular tachycardia; in peripheral vascular spasms (intermittent claudication, Raynaud’s disease, obliterating thrombangiitis).

In central, peripheral and mixed forms of hereditary retinal pigmentary degeneration.

Active ingredient

Triphosadenin

Composition

1 ml of solution for intravenous injection contains:
active ingredient: adenosine triphosphoric acid 10 mg.
excipients: sodium hydroxide solution 2 M (to pH 7.0-7.3), water for injection.

How to take, the dosage

Sodium adenosine triphosphate is administered intramuscularly or intravenously.

For the treatment of muscular dystrophies, peripheral circulatory disorders in the first 2-3 days 1 ml intramuscularly once a day is prescribed, on subsequent days – 1 ml 2 times a day or immediately 2 ml once a day. The course of treatment is 30-40 days. If necessary the course shall be repeated in 1-2 months.

In case of hereditary retinal pigmentary degeneration 5 ml by intramuscular injection 2 times a day, 6-8 hours apart, daily for 15 days. If necessary, the courses can be repeated at intervals of 8-12 months.

To stop supraventricular tachyarrhythmias, inject intravenously 1-2 ml for 5-10 seconds (effect observed after 20-40 seconds). If necessary, the same dose is administered again after 2-3 minutes.

Interaction

When used together with dipyridamole, the effects of dipyridamole, in particular the vasodilator effect, are enhanced.

There is some antagonism when co-administering the drug with purine derivatives (caffeine and theophylline).

The drug should not be administered concomitantly with cardiac glycosides in high doses because of an increased risk of cardiovascular adverse reactions.

Concomitant use with xanthinol nicotinate decreases the effect of sodium adenosine triphosphate.

Carbamazepine may increase the effects of adenosine and lead to the development of blockade.

Special Instructions

Intravenous administration of the drug should generally be performed in a hospital setting, under medical supervision, with control of cardiac function, slowly, after which it is advisable to measure the blood pressure.

Cautious use if there is significant bradycardia, sinus node weakness syndrome, AV blockade degree I, tendency to arterial hypotension.

The drug should not be administered simultaneously with cardiac glycosides in high doses.

Contraindications

• Individual hypersensitivity to the drug,
• acute myocardial infarction,
• arterial hypotension,
• Hypertension.severe bradyarrhythmia,
• AV-blockade of degree II-III,
• decompensated stage of heart failure,
• cardiogenic shock and other shocks,
• QT prolongation syndrome,
• hemorrhagic stroke;
• inflammatory lung diseases,
• chronic obstructive pulmonary disease (e.g., bronchial asthma);
• pregnancy,
• breastfeeding period,
• childhood.

.

Side effects

Central nervous system: headache, dizziness, momentary loss of consciousness, feeling of compression in the head, phobias.

Visual organs: blurred vision.

Gastrointestinal tract: nausea, metallic taste in the mouth, increased gastrointestinal motility (when administered intravenously).

Cardiovascular system disorders: palpitations, sensation of discomfort in the chest, tachycardia or bradycardia, arterial hypotension, arrhythmia, AV conduction disorders (atrioventricular block), asystole.

Musculoskeletal system: pain in the arms, back, neck.

Urinary system disorders: increased diuresis.

Respiratory system: shortness of breath, bronchospasm.

Skin and subcutaneous tissue changes: facial hyperemia, itching, skin rash.

Disorders at the injection site: tingling sensation.

Allergic reactions: hypersensitivity reactions, allergic dermatitis, urticaria, anaphylactic shock.

General disorders: increased sweating, hyperthermia, feeling of fever.

Overdose

Symptoms: dizziness, arterial hypotension, momentary loss of consciousness, arrhythmia, atrioventricular block of II and III degree, asystole, bronchospasm, ventricular disorders, sinus bradycardia and tachycardia. The development of allergic reactions is also possible.

Treatment. Injection of the drug is stopped immediately and cardiotonic agents are prescribed. Therapy is symptomatic. Xanthines (eufylline, theophylline) are competitive adenosine antagonists.